Philadelphia, PA, January 14, 2013 - Bipolar disorder is a severe mood disorder characterized by unpredictable and dramatic mood swings between the highs of mania and lows of depression. These mood episodes occur among periods of 'normal mood', termed euthymia.
Prior research has clearly shown that brain emotion circuitry is dysregulated in individuals diagnosed with bipolar disorder. It is thought that these disturbances impair one's ability to control emotion and contribute to mood episodes.
Continuing this line of research, the January 15th issue of Biological Psychiatry reports the results of a study conducted by scientists from Indiana University School of Medicine. These investigators used functional magnetic resonance imaging (fMRI) to investigate which areas of the brain showed abnormal activation while patients in different mood phases of bipolar disorder tried to control their response to emotional and non-emotional material.
This allowed them to analyze brain activation patterns based on patient mood (manic, depressed, or euthymic) and stimuli type (emotion versus no emotion and happy versus sad). Because medication effects on brain activation have been observed in some studies, the researchers recruited only unmedicated volunteers.
They found that bipolar depressed patients abnormally activated brain areas when they had to withhold responses to sad faces. Manic patients, on the other hand, had abnormal activation regardless of whether they were trying to withhold response to sad faces, happy faces or non-emotional material. Even the euthymic bipolar subjects showed abnormal activation of cortical areas of the brain while withholding responses to emotional faces.
These findings suggest that distinct circuit dysfunctions may contribute to different features of emotion dysregulation in bipolar disorder.
Professor and senior author Dr. Amit Anand said, "This study provides important information regarding brain areas that may be important in controlling response to emotional material and the functional abnormalities in these areas in mood disorders."
"It is interesting that subtly different circuits distinguish symptomatic and non-symptomatic patients with bipolar disorder when they are suppressing their happy and sad reactions," commented Dr. John Krystal, Editor of Biological Psychiatry. "These findings may have implications for the refinement of circuit-based treatments for bipolar disorder including neurostimulation and psychotherapy."
The article is "Emotional Response Inhibition in Bipolar Disorder: A Functional Magnetic Resonance Imaging Study of Trait- and State-Related Abnormalities" by Tom A. Hummer, Leslie A. Hulvershorn, Harish S. Karne, Abigail D. Gunn, Yang Wang, and Amit Anand (doi: 10.1016/j.biopsych.2012.06.036). The article appears in Biological Psychiatry, Volume 73, Issue 2 (January 15, 2013), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Amit Anand at +1 317 963 7300 or firstname.lastname@example.org.
The authors' affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 129 Psychiatry titles and 16th out of 243 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2011 Impact Factor score for Biological Psychiatry is 8.283.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Rhiannon Bugno, Editorial Office
+1 214 648 0880